We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · December 16, 2019

ASH 2019: Carfilzomib, Dexamethasone, and Daratumumab Triplet Offers Benefits in Relapsed/Refractory Multiple Myeloma

Outcomes are superior when compared with carfilzomib and dexamethasone alone

PracticeUpdate Editorial Team


Further Reading